ProMIS NeurosciencesのRSI
ProMIS NeurosciencesのRSIは何ですか。
ProMIS Neurosciences, Inc.のRSIは47.13です。
RSIの定義は何ですか。
相対力指数 (The relative strength index, RSI 14)は、一定期間における損益の規模を比較して、証券の価格変動の速度と変動を測る指標です。
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
OTCのセクタHealth CareにおけるRSIの企業と比べるProMIS Neurosciences
ProMIS Neurosciencesは何をしますか。
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ProMIS Neurosciencesと類似のrsi
- Meenakshi EnterprisesのRSIは47.11です。
- Techno Electric & EngineeringのRSIは47.11です。
- BSLのRSIは47.11です。
- Georgia Power CoのRSIは47.12です。
- TeamViewer AGのRSIは47.12です。
- Alphamab OncologyのRSIは47.12です。
- ProMIS NeurosciencesのRSIは47.13です。
- Gulf Marine Services PLCのRSIは47.14です。
- Aytu BioPharma IncのRSIは47.14です。
- Titanium Transportation IのRSIは47.14です。
- Queen's Gambit Growth CapitalのRSIは47.14です。
- Victory MetalsのRSIは47.14です。
- OP BancorpのRSIは47.15です。